Ameriprise Financial Inc. reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 36.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,493,992 shares of the medical equipment provider’s stock after selling 1,448,926 shares during the quarter. Ameriprise Financial Inc. owned about 1.23% of Zimmer Biomet Holdings worth $292,011,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Commonwealth Equity Services Inc increased its holdings in Zimmer Biomet Holdings by 2.8% in the 3rd quarter. Commonwealth Equity Services Inc now owns 33,552 shares of the medical equipment provider’s stock valued at $3,928,000 after buying an additional 914 shares during the period. Advisors Asset Management Inc. increased its holdings in Zimmer Biomet Holdings by 17.2% in the 3rd quarter. Advisors Asset Management Inc. now owns 63,941 shares of the medical equipment provider’s stock valued at $7,487,000 after buying an additional 9,376 shares during the period. Commerce Bank increased its holdings in Zimmer Biomet Holdings by 0.8% in the 3rd quarter. Commerce Bank now owns 219,815 shares of the medical equipment provider’s stock valued at $25,738,000 after buying an additional 1,644 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Zimmer Biomet Holdings by 11.2% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 637,006 shares of the medical equipment provider’s stock valued at $74,587,000 after buying an additional 64,255 shares during the period. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in Zimmer Biomet Holdings by 5.5% in the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 49,853 shares of the medical equipment provider’s stock valued at $5,837,000 after buying an additional 2,619 shares during the period. 85.36% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/23/zimmer-biomet-holdings-inc-zbh-holdings-reduced-by-ameriprise-financial-inc.html.

A number of research firms have recently weighed in on ZBH. Cantor Fitzgerald set a $137.00 price target on shares of Zimmer Biomet Holdings and gave the company a “hold” rating in a research note on Thursday, July 27th. Canaccord Genuity downgraded shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and reduced their price target for the company from $141.00 to $135.00 in a research note on Friday, July 28th. Piper Jaffray Companies restated a “buy” rating and issued a $135.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 28th. Oppenheimer Holdings, Inc. set a $137.00 price target on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a research note on Friday, July 28th. Finally, Leerink Swann raised their price target on shares of Zimmer Biomet Holdings from $141.00 to $146.00 and gave the company an “outperform” rating in a research note on Friday, July 28th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet Holdings presently has a consensus rating of “Hold” and a consensus target price of $133.71.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at $113.07 on Thursday. The stock has a market cap of $22,790.00, a P/E ratio of 14.07, a PEG ratio of 1.76 and a beta of 1.17. Zimmer Biomet Holdings, Inc. has a 1 year low of $99.11 and a 1 year high of $133.49. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The firm’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter last year, the firm posted $1.79 EPS. equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current fiscal year.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.